Drosophila melanogaster p53 has developmental stage-specific and sex-specific effects on















































The  p53 gene encodes a transcription factor that 
regulates apoptosis and metabolism and is mutated in 
the majority of human cancers [1, 2]. The p53 protein 
functions as a tetramer with various protein domains 
















































tional transactivation.   Drosophila contains a single 
p53 gene with a structure similar to humans [3-6] 
including two promoters, and the major protein products 
are of similar size: 393 amino acid residues for the 
human protein, Hp53, and 385 amino acid residues for 
the  Drosophila protein, Dmp53 (Drosophila protein 
diagrammed in Figure 1A).  The  central  DNA  binding   






































type  p53  in  aging  remains  unclear.  Here  conditional  over‐expression  of  both  wild‐type  and  mutant  p53  transgenes
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conservation with Hp53 [3]. The other domains of 
Dmp53 show less obvious sequence similarity to Hp53, 
but appear conserved in function. Similar to the N-
terminal transcriptional activation domain of Hp53, the 
N-terminus of Dmp53 contains a high proportion of 
acidic residues, and Dmp53 has been shown to bind to 
conserved p53 response elements and activate 
transcription [3]. The C-terminus of Hp53 contains a 
basic region (9/26 residues) that can bind either DNA or 
RNA, and the C-terminus of Dmp53 is also relatively 
basic (6/24 residues).  Finally, the oligomerization 
domain is located in the C-terminal portion of Hp53, 
and the corresponding region of Dmp53 contains a 
conserved critical Gly “hinge” residue, and appears 
active in oligimerization based on yeast two hybrid 
assays.  The p53 message is expressed at very low 
levels in adult tissues, with some enrichment indicated 
for the eye, malphigian tubule (similar to mammalian 
kidney), and female germ cells [7, 8]. 
 
Mutant forms of p53 lacking function of a particular 
domain can have powerful dose-dependent effects that 
are often dependent upon the presence of wild-type p53 
[3, 9-11].  For example, specific truncated forms of 
mouse p53 can cause enhanced cancer resistance and 
accelerated aging phenotypes, generally interpreted as a 
state of p53 hyperactivation [12].  Based on studies in 
mammals it has been suggested that p53 may exhibit 
antagonistic pleiotropy between life-cycle stages, in that 
























tance in young animals, but may promote aging in old 
animals [9, 13-15].  Recently p53 gene activity was 
found to limit the life span of C. elegans hermaphrodites, 
and this effect was dependent upon the activity of the 
insulin/IGF1-like signaling (IIS) transcription factor gene 
Daf-16/FOXO [16].  In Drosophila, several dominant 
p53 mutations and transgenes have been characterized, 
that generally appear to antagonize p53 activity [3].   
Nervous-tissue expression of one of these dominant p53 
transgenes (p53 point mutation 259H) was found to 
inhibit IIS and extend life span in females [17, 18].   
However it remains unclear if and how p53 might 
normally affect the life span of Drosophila males and 
females.  Here the wild-type form of p53, as well as 
mutant forms, were assayed for effects on Drosophila life 




Transgenic manipulation of p53 in adult flies 
 
Drosophila p53 transgenes were assayed for effects on 
life span both in adults and during larval development 
(see below).  The conditional transgenic system 
Geneswitch  [19-21] was used to over-express both 
wild-type and mutant forms of p53.  With the 
Geneswitch system transgene expression is triggered by 
feeding flies (or larvae) the drug RU486/Mifepristone.  
A Geneswitch driver strain called Act-GS-255B was 
used (Table 1, strain 9), where the tissue-general 
actin5C promoter drives expression of the Geneswitch 





















Strain  #            Genotype        Group  (notes) 
2       w[1118] ; + ; Df(3R)Exel6193, P{XP-U}Exel6193 /TM6B, Tb (BL7672)  -     (Chromosomal Def uncovers p53)  
3       y[1] w[1118] ; + ; p53[5A-1-4] (BL6815)        -    (deletion of p53 gene) 
4       y[1] w[1118] ; + ; p53[11-1B-1] (BL6816)        M  (pt mutant) 
5       w[1118] ; p53[1] / TM6B, Tb                        M  (the same pt mutant as line 4) 
6       w[1118] ; + ; +                           +    
7       Oregon R ( + ; + ; +)                          +    
8        y[1] w[67c23]; P{EPgy2}p53[EY14108] (BL 20906)                  M  (the P-insertion disrupts the B variant) 
9        w ; P{Switch}Actin 255B                        (GeneSwitch Act-GS-255B driver) 
16       y[1]w[1118]; P{w[+mC]=UAS-p53.Ex}3/T(2;3)TSTL, CyO:TM6B, Tb     (UAS-p53 wild type) 
17      w ; P{w[+mC]=GUS-p53}2.1           (UAS-p53 wild type - CDM26) 
18      w; P{w[+mC]=GUS-p53.Ct}AF51                      (C-terminal p53 - AF51) 
19      w[1118]; +; P{w[+mC]=GUS-p53.Ct}B440/TM6B, Tb                 (C-terminal p53 - B440) 





























































GS-255B driver produces expression of UAS-
containing target constructs in all the tissues of either 
larvae or adults [19, 22]: detailed characterization of the 
system using UAS-GFP reporter constructs 
demonstrates that the Act-GS-255B driver produces 
abundant transgene expression throughout all of the 
tissues of both adult flies and larvae, for both male and 
female animals, with slightly less (but still abundant) 
expression in adult males relative to females [22]. All of 
the flies examined in this study are the progeny of a 
cross; for example “16-9” flies are the progeny of a 
cross of males of strain 16 (containing the UAS-p53 
wild-type transgene) with females of strain 9 
(containing the Act-GS-255B Geneswitch driver) to 
generate progeny containing both constructs (strains 
summarized in Table 1); in all cases crosses are 
indicated with the male parent genotype first, and the 
female parent genotype second.  The RU486 drug itself 
had no significant effect on male or female life span 
when administered to adults (Figure 2A; statistical 
analyses summarized in Supplementary Table S1).   
When wild-type p53 was over-expressed specifically in 
adult flies, it had a negative effect (-16%) on mean life 
span in females (cross 16-9: 95% bootstrap CI for the 
ratio of the means [-21.11 - 11.61], log-rank p-value = 
2.21 ×10
-6), and a positive effect (+6%) on mean life 
span in males (cross 16-9: 95% bootstrap CI [2.36 - 
10.37], log-rank p-value  = 6.97 ×10
-3) (Figure 2B; 
Supplementary Table S1).  Slightly larger changes were 
observed for median life spans (Supplementary Table 
S1), and similar results were obtained with multiple 
independent transgenic insertions of p53 wild-type (data 
not shown).  In contrast, adult-specific over-expression 
of the dominant mutant p53 (point mutation p53-259H) 
transgene did not have a negative effect on female life 
span, and instead female life span tended to be 
increased (cross 20-9: +7%, 95% bootstrap CI [4.09 - 
9.72], log-rank p-value = 4.05 ×10
-8) (Supplementary 
Figure S1B; Supplementary Table S1) [22], and similar 
results were obtained with p53 dominant mutant 
transgene p53-Ct[B440] (Supplementary Figure S1C; 
Supplementary Table S1).  Because these Drosophila 
p53 dominant mutation transgenes are generally 
expected to antagonize the activity of wild-type p53, the 
data are consistent with wild-type p53 having a negative 
effect on adult female life span. The negative effect on 
life span of wild-type p53 over-expression in adult 
females and the lack of negative effect with dominant 
mutant  p53 transgenes was also confirmed using the 
FLP-out conditional system [23] to cause transgene 
over-expression (data not shown). Taken together, these 
data indicate that in adult flies, p53 inhibits life span in 















wild‐type  over‐expression  during  female  larval  development  and 
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Transgenic manipulation of p53 during development 
 
A strikingly different set of results was obtained when 
Drosophila p53 transgenes were expressed specifically 
during larval development.  When administered only 
during larval development, the drug RU486 itself had 
no effect on subsequent adult female life span, and a 
small negative effect on subsequent adult male life span 
(~-4%; Supplementary Table S1).  Over-expression of 
wild-type p53 at high levels during larval development 
was toxic to both males and females, in that no male 
adults were produced, and only three female adults 
(escapers) were obtained (Figure 2B).  Intriguingly, the 
three female escapers had unusually long life spans: 86 
days, 92 days, and 96 days, respectively. To determine 
if this apparent life span increase was significant, and to 
investigate the developmental effects of wild-type p53 
over-expression in greater detail, the over-expression 
was modulated by titration of the RU486/Mifepristone 
drug, in replicated experiments.  Titration of wild-type 
p53 over-expression during development again 
indicated toxicity at high levels of expression, with 
greater toxicity evident for males (Supplementary Table 
S2).  Strikingly, at lower levels of induction, wild-type 
p53 produced both female and male adults with 
increased mean and maximal life span (Figure 2C; 
Supplementary Figure S1E-F; Table S2; female: +14%, 
95% bootstrap CI [9.29 – 19.27]; log-rank p-value ≈ 0; 
male: +15%, 95% bootstrap CI [10.54 – 19.30]; log-
rank p-value = 4.97 × 10
-7).  These data demonstrate 
that high-level expression of p53 can be toxic during 
development, whereas moderate over-expression of p53 
during development can cause increased life span in the 
resulting male and female adults.   Consistent with this 
conclusion, expression of the dominant mutant 
transgenes during development tended to decrease the 
life span of the resultant male and female adults 
(Supplementary Figure S1A-D, Table S1). 
 
Effect of mutations in the endogenous p53 gene 
 
To confirm the effects of p53 on Drosophila life span, 
flies were examined that had a deletion or mutation of 
the endogenous p53 gene (mutations diagrammed in 
Figure 1B; strains listed in Table 1) [24]. Multiple trans-
heterozygous  p53 wild-type and mutant allele 
combinations were assayed for life span simultaneously 
as a control for genetic background effects and environ-
mental effects (the “L” cohort, data summarized in 
Supplementary Tables S3, S4). This was done using two 
p53 wild-type strains (called the “+” group; strains 6 
and 7), two strains containing p53 null mutation (called 
the “-” group; strains 2 and 3), and three strains con-
taining  p53 dominant mutations  (called the “M” group; 
 
strains 4, 5 and 8), and crossing each strain to each of 
the others in a “round-robin” approach.  In this way 
each of the various p53 genotypes (+/+, -/-, +/-, +/M, -
/M, M/M) represents the average of multiple specific 
genetic backgrounds.  This approach avoids the 
potential complication of identifying p53 effects that 
might be specific to only one particular genetic 
background, such as would be created by using a 
backcrossing strategy.  
 
In flies with mutations of the endogenous p53 gene, the 
effect on life span should be the sum of the effects of 
p53 at various life-cycle stages, both positive and 
negative (diagrammed in Figure 1D); and indeed, p53 
mutations were found to have a significant effect on life 
span in both sexes (ANOVA, p < 0.0001; 
Supplementary Table S5):  Null mutation (-/-) of the 
p53 gene increased mean female life span by +13% 
(95% bootstrap CI [9.00 -17.28]; log-rank p-value ≈ 0) 
relative to wild-type (+/+) controls (Figure 3A; 
Supplementary Figure S2A; Supplementary Table S4).  
In the heterozygous p53 mutant genotype (-/+) average 
female life span was also increased relative to wild-type 
controls by +11% (95% bootstrap CI [8.41 - 13.59]; 
log-rank p-value ≈ 0).  In male flies null mutation (-/-) 
of the p53 gene increased mean life span by +12% (95% 
bootstrap CI [4.92-14.50]; log-rank p-value ≈ 0), 
whereas the effect of heterozygous mutation was 
smaller, yielding mean life span increases of +5.5% 
(95% bootstrap CI [2.15 – 7.53]; log-rank p-value ≈ 0) 
(Figure 3B; Supplementary Figure S2B; Supplementary 
Table S4). However, as seen below (Figure 4A, 
Supplementary Figure S4), the life span increases in 
p53 mutant males were not consistently observed when 
crosses were done in the opposite direction, and 
therefore may not be biologically significant. Similar 
effects of p53 null (-/-) and heterozygous (+/-) 
genotypes were obtained when the experiments were 
repeated using different culture conditions (richer food 
source and presence of mates) that yield shorter overall 
life spans (the “W” cohort; Supplementary Figure S3; 
Supplementary Tables S6, S7). Taken together, these 
data with endogenous p53 gene mutations support the 
conclusion that, in sum, p53 limits the life span of 
female flies, with smaller and more variable effects in 
male flies. 
  
Several Drosophila p53 dominant mutations (M) were 
examined and found to have complex effects on adult 
life span, depending upon the particular allele, and 
whether or not a wild-type copy of p53 was present in 
the background (Figure 3; Supplementary Figures S2, 
S3).  Some of the variability in life span across geno-
types is expected to result from differences in genetic 
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mutations and their interactions with genetic background 
has recently been reviewed [25]. Strikingly, when the 
data for the various p53 genotypes in the L cohort were 
grouped to control for genetic background effects, the 
dominant mutations tended to increase life span in 
females (+/M, -/M, M/M), and to decrease life span in 
males (+/M, M/M) (Figure 3; Supplementary Figure S2; 
Supplementary Table S4). Since the Drosophila  p53 
dominant mutations are generally expected to antagonize 
wild type p53 function, the increased life span of +/M 
females relative to wild type (+/+) is consistent with the 
results obtained above suggesting that, in sum, p53 limits 
the life span of females. However, for the M/M genotype 
flies, a wild-type copy of the entire p53 gene is not pre-







































in life span in females and the greatest decrease in life 
span in males.  Therefore, these data suggest that the 
mutant forms of p53 may have sexually antagonistic 
effects on Drosophila life span that are not necessarily 
dependent upon the presence of a wild-type p53. 
Strikingly, these effects of dominant mutations on life 
span were highly dependent upon environment, since in 
the W cohort the dominant mutations tended to decrease 
life span in both males and females (Supplementary 
Figure S3; Supplementary Table S7). It will be of interest 
in the future to determine what is the mechanism for 
these opposite effects of dominant p53 mutations in 
males versus fe-males, and to determine if the dramatic 
gene-by-environ-ment effect of p53 dominant mutations 
in females is due to the presence of mates, the richer food 
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In an effort to control for possible maternal effects and 
X chromosome effects, several life span assays were 
repeated with the crosses done in both directions 
simultaneously, i.e., varying which strain serves as 
mother or father for the cross (Supplementary Figure 
S4).  An increase in life span of p53 null mutant (-/-) 
flies relative to wild-type (+/+) controls was obtained in 
female progeny regardless of cross direction 
(Supplementary Figure S4; Supplementary Table S8), 
thereby ruling out a primary effect of maternal 
genotype. In males a consistent change in life span was 
not observed, in that although the null mutants exhibited 
slight differences in life span compared to controls, the 
direction of change differed depending on the direction 
of the cross. Furthermore, while the survival curves of 
many of the reverse cross pairs differed from one 
another in both sexes (log-rank test, data not shown), in 
females there was strong concordance and highly 
significant results from comparisons of survival curves 
in both cross directions and relative to both controls, 
while this was not the case for males (Supplementary 
Table S8).  These results demonstrate that the increased 
life span in females due to p53 mutation cannot be 
simply due to maternal or X chromosome effects, and in 
conjunction with the above findings, these data again 
suggest that p53 preferentially limits the life span of 
female flies. 
 
Sex-specific effects p53 on fly stress resistance 
 
Drosophila  p53 is required for normal resistance of 
larval cells and tissues to certain kinds of stress, for 
example, ionizing radiation and UV toxicity [26, 27], 
and third-instar larvae that are null for p53 exhibit 
decreased survival when challenged with 4,000 Rads of 
ionizing radiation [28].  To determine if p53 genotype 
might have sex-specific effects on stress resistance in 
adult flies, male and female flies that were either wild-
type or mutant for p53 were subjected to two types of 
life-shortening stress, ionizing radiation and 100% 
oxygen atmosphere, in replicated experiments (Figure 4, 
Supplementary Table S9).  Treatment with 90,000 Rads 
of gamma-irradiation on day 10 of adult age reduced 
adult life spans by half, and p53 mutant female flies 
were again found to have greater mean life span than 
wild-type controls (+/-: +18%, 95% bootstrap CI [13.13 
- 23.36]; log-rank p-value = 0;  -/-: +13%, 95% 
bootstrap CI [9.09 - 16.71]; log-rank p-value = 2.98 
×10
-4).  In contrast, p53 mutations were found to 
slightly reduce the survival of female flies subject to 
100% oxygen atmosphere (-/+: not significantly 
different than wild-type; 
 -/-: -4%, 95% bootstrap CI 
[−5.06 - −3.34]; log-rank p-value = 1.28 ×10
-13). In 
males,  p53 null mutants subject to ionizing radiation 
had significantly reduced mean life span, whereas 
heterozygotes fared slightly better than wild-type (+/-:  
+4%, 95% bootstrap CI [1.80 – 6.00]; log-rank p-value 
= 2.02 ×10
-7; -/-: -19%, 95% bootstrap CI [−20.68 - 
−17.06]; log-rank p-value ≈ 0). As with females, p53 
gene mutations tended to reduce male survival in 
response to a 100% oxygen environment (+/-: −4%, 
95% bootstrap CI [−4.38 - −3.05]; log-rank p-value  = 
4.44  × 10
-16; -/-:  −15%, 95% bootstrap CI [−16.13 - 
−14.10]; log-rank p-value  ≈ 0). Therefore, wild-type 
p53 tended to favor the survival of both sexes under 
100% oxygen stress conditions, yet was detrimental to 
female life span in flies subject to ionizing radiation. 
Therefore the results for adults subject to ionizing 
radiation were similar to those observed during normal 
aging: normal p53 function increased survival of males 
and decreased survival of females. The fact that p53 
favored the survival of both sexes under the more 
severe life-shortening condition of 100% oxygen stress 
may be indicative of a threshold effect on survival that 




In these experiments a combination of genetic and 
transgenic approaches were used to study how p53 
affects the life span of male and female Drosophila.  
The conditional transgenic system Geneswitch was 
employed to produce tissue-general expression of p53, 
either during development or specifically in adults.   
Detailed characterization of the Geneswitch driver 
strain (“Actin-GS-255B”) using GFP reporter constructs 
demonstrated that the system yields truly tissue-general 
expression during larval development, as well as tissue-
general expression in both male and female adults [22].  
The data indicate that Drosophila  p53 has effects on 
adult life span that are antagonistically pleiotropic 
between developmental stages and sexes (summarized 
in Figure 1A).  One advance of the present study is that 
life span effects were identified using transgenes 
encoding the full length, wild-type form of Drosophila 
p53 protein, as well as ones encoding mutant forms. In 
adults, wild-type p53 over-expression limited life span 
in females and favored life span in males. In contrast, 
during development, p53 over-expression acted in a 
dose-dependent manner to either reduce or increase the 
subsequent longevity of both male and female adults: 
high level expression during development was 
detrimental, whereas moderate over-expression 
produced increased life span.  The dominant mutation 
transgenes generally produced the opposite effect of 
wild type p53 transgenes, in both males and females.  
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transgenes on male and female life span cannot be 




















































transgene expression in males versus females, or to 
some differential toxicity of the encoded proteins in 
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were obtained from analysis of the endogenous p53 
gene:  Null mutation of the endogenous p53 gene 
increased life span in females, and had smaller, more 
variable effects on male life span.  The effects of p53 on 
adult fly survival under stress conditions were also sex-
biased:  wild-type p53 was found to favor the survival 
of both sexes under 100% oxygen stress conditions, yet 
to be detrimental to female life span in flies subject to 
ionizing radiation. In these experiments p53 expression 
and function is being altered in all of the tissues of the 
animal simultaneously, and therefore the effects 
observed are the sum of any possible tissue-specific 
effects of p53.  Indeed our results suggest that the 
positive and negative effects of p53 o n  l i f e  s p a n  
observed here with tissue-general alterations are 
comprised of a mix of both positive and negative tissue-
specific effects, that combine to result in the observed 
opposite effects in males versus females (J.S. and J.T., 
2009 Experimental Gerontology, in press). 
 
The data presented here indicate that p53 null mutation 
increases life span in female flies, with smaller, more 
variable increases observed for male flies.  Helfand and 
coworkers have previously reported that p53 null 
mutant male and female flies were sickly, with a 
shortened life span, however, statistical analysis was not 
presented [17]. One possibility is that the apparent 
reduction in life span and vigor previously reported for 
p53 null flies may have resulted from inbreeding 
depression in the homozygous mutant flies used in that 
study.  In contrast, in the experiments presented here, 
multiple trans-heterozygous p53 null mutant genotypes 
were examined, so as to reduce possible inbreeding 
effects, and thereby reveal the life span benefit of p53 
null mutations.  Helfand and coworkers also analyzed 
the effect on life span of nervous system-specific 
expression of two p53 dominant mutant transgenes, a C-
terminal fragment transgene (p53-Ct), and the point 
mutant (p53-259H).  They found that nervous system 
expression of p53-Ct throughout both development and 
adulthood increased female life span by +58%, and 
increased male life span by +32% [17].  Because the 
dominant mutations are generally expected to 
antagonize p53 activity, their results are consistent with 
our conclusion that, in sum, p53 limits life span in 
females, with smaller effect in males (summarized in 
Figure 1D). Using the Elav-Geneswitch driver to restrict 
expression to the adult nervous system, Helfand and 
coworkers found that the p53-Ct transgene increased 
female life span by +18% to +26%, and the p53-259H 
transgene increased female life span by +11% to +13%, 
again consistent with our finding that p53 limits the life 
span of adult females.  Indeed, using the tissue-general 
Act-GS-255B driver to restrict transgene expression to 
adults, we also found that the p53-Ct and p53-259H 
transgenes produced an increase in median life span in 
females (Supplementary Figure S1A-D) [22].  For 
adult-specific expression in male nervous system, 
Helfand and coworkers reported life span data for only 
two assays, both using the p53-Ct transgene: using a 
high-calorie food condition, male life span was reported 
to be increased by +13%, whereas using a low-calorie 
food, male life span was unchanged, and results for 
normal food were not presented [17].  That result might 
at first appear to be partly inconsistent with our 
conclusion that p53 favors life span in adult males, 
however, there are several possible explanations that 
might reconcile these results.  First, the previous 
experiment involved the p53-Ct transgene, encoding the 
p53 C-terminal fragment, and data from mammals 
suggests that certain dominant p53 mutants are capable 
of either antagonizing or promoting p53 activity, 
depending upon the level of expression and the cellular 
context [11].  Second, the life span increase was 
observed only under a high-calorie food condition, and 
our data suggest sex-specific interactions between 
dominant  p53 mutations and diet/environment with 
regard to life span (Figure 3, Supplementary Figure S2). 
Under our conditions and using tissue-general 
expression, we found that adult-specific expression of 
the dominant mutant p53 transgenes tended to decrease 
male life span (Supplementary Figure S1, Table S1), 
consistent with our conclusion that p53 normally favors 
adult male life span. Finally, the effects of tissue-
general expression, as tested here, will be the sum of all 
tissue-specific effects, be they positive or negative. 
Indeed our results suggest that the positive and negative 
effects of p53 on life span observed here with tissue-
general alterations are comprised of a mix of both 
positive and negative tissue-specific effects (J.S. and 
J.T., 2009 Experimental Gerontology, in press), that 
combine to result in opposite effects in males versus 
females (summarized in Figure 1D). Therefore, the 
previous results from the Helfand group (with the 
possible exception of a single assay of males under a 
high-calorie food condition), are generally consistent 
with the results presented here.  
 
One possible mechanism by which p53 might act in 
adult flies to preferentially limit female life span is by 
stimulating IIS, since IIS appears to preferentially limit 
life span in females of Drosophila and other species 
[29, 30]. Studies in mammals provide precedent for 
crosstalk between p53 and the IIS pathway, including 
the target transcription factor FOXO, in regulating both 
aging and cancer [31, 32].  Consistent with this idea, 
life span extension in Drosophila females produced by 
nervous system-specific expression of the dominant 
mutant p53-259H transgene was found to correlate with 
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mutation of the p53 homolog cep-1 increased life span 
of adult hermaphrodites, and this increase required the 
function of the IIS target transcription factor gene Daf-
16/FOXO [16]. To definitively rule in (or out) a role for 
IIS in Drosophila p53 life span effects will require 
future assays in the presence and absence of the Foxo 
transcription factor.  
 
Another possible mechanism by which p53 might affect 
life span is by altering proliferation or causing apoptosis 
in particular cell types.  For example, ablation of germ-
line cells in adult animals by forced over-expression of 
the bam gene caused increased life span in males and 
females [33]. However, while germ line ablation might 
be attractive as a possible mechanism for the increased 
life span observed in p53-over-expressing males, it is 
not consistent with the life span decrease observed in 
females.  Alternatively, over-expression of wild-type 
p53 specifically in adult diploid cells using an escargot-
GAL4 driver caused ablation of most stem cells in the 
gut, and gut stem cell proliferation appears to be more 
rapid in females than in males [34].  While this might be 
attractive as a possible mechanism for the life span 
decrease observed in p53-over-expressing females, it is 
not consistent with the life span increase observed in 
males; indeed other experiments involving disruption of 
adult diploid cell function caused an equally dramatic 
decrease in life span in both sexes [35].  It will be of 
interest in the future to ask if p53 might be affecting life 
span through highly sex-specific or sexually opposite 
effects on cell proliferation and survival.  Notably, over-
expression of strong caspase inhibitors and other 
apoptosis and senescence regulatory genes in adult flies 
did not yield increased life span in either sex, and where 
negative effects on life span were observed, such as 
with  wingless and activated Ras, the negative effects 
were similar in males and females [22].  Those results 
tend to suggest that p53 may be acting through some 
other mechanisms, such as alterations in metabolism or 
autophagy.  Additional possible mechanisms by which 
p53 might affect life span include sex-specific 
alterations in behavior, such as food intake, or 
potentially costly activities such as movement or 
aggression. 
 
In these experiments Drosophila p53 was also found to 
have sex-specific effects on survival under stress 
conditions.  Wild-type p53 favored the survival of both 
sexes under 100% oxygen stress, yet was detrimental to 
female life span in flies subject to ionizing radiation.   
This may be indicative of a threshold effect on survival 
that is sex-specific. Mechanistically the ability of p53 to 
either favor survival or mortality may be related to 
p53’s ability to regulate both repair and apoptotic 
pathways [1, 36-38], and perhaps the functional 
connection between p53 and FOXO in response to 
oxidative stress [25]. In line with our findings, C. 
elegans hermaphrodites that are long-lived due to p53 
(cep-1) mutation did not demonstrate increased 
resistance to oxidative (or UV) stress [16], however 
resistance to gamma irradiation was not examined.   
Strikingly, in C. elegans hermaphrodites, p53 has 
recently been found to increase life span in response to 
mild mitochondrial stress, and to decrease life span in 
response to severe mitochondrial stress, consistent with 
a threshold effect on survival [39] ; however effects in 
males have not been reported.  In mice, reduced p53 
function results in resistance to lethality caused by 
moderate gamma irradiation and increased sensitivity to 
severe irradiation [40,41], again suggestive of a 
threshold effect, however any potential sex-bias has not 
been reported.  Finally, long-lived female Drosophila 
that over-expressed dominant-mutant p53 in neurons 
exhibited increased resistance to the oxidative stressor 
paraquat [17]; however effects in males were not 
reported. Taken together the data are consistent with a 
model in which p53 has a threshold effect on survival 
under stress, and the threshold for the transition from 
favorable to detrimental depends upon the type of stress 
and the sex of the animal.  Such a threshold model is 
consistent with extensive data from mammals and 
model systems demonstrating that p53 can either favor 
oxidative stress resistance and cell survival, or favor 
oxidative stress and cell death, depending upon the 
cellular and environmental context, and the degree of 
activation of p53 [38]. In mammals, physiological 
levels of p53 activity appear to maintain normal cellular 
redox status, through sustained expression of 
antioxidant genes (e.g., Sesn1&2, GPX1, AIF) and 
metabolic genes (e.g., SCO2, PGM, TIGAR).  In 
contrast, hypo-physiological levels of p53 activity can 
suppress expression of antioxidant genes (e.g., 
Sesn1&2, GPX1) and cause increased oxidative stress. 
Similarly, hyper-physiological levels of p53 activity can 
induce pro-oxidant and apoptosis-promoting genes (e.g., 
NQO1, POX, BAX, PUMA, p66shc), and/or cause an 
imbalance in expression of antioxidant genes (e.g., 
MnSOD, PIG12, ALDH4, GPX), and again cause 
increased oxidative stress [38].  
 
Antagonistic pleiotropy of gene function between 
younger and older animals is generally accepted as one 
of the most likely genetic mechanisms underlying aging 
[42]; however, specific genes exhibiting such pleiotropy 
have generally not been identified.  One notable 
exception is data from mammals that suggests p53 
exhibits antagonistic pleiotropy between developmental 
stages.  At young ages p53 favors fecundity and favors 
survival by acting as a tumor suppressor, yet at late ages 
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through other mechanisms [13, 43]. Increasing evidence 
suggests that genes can also exhibit antagonistic 
plieotropy of function between the sexes, affecting a 
variety of traits including reproductive fitness and life 
span [30, 44-47]. The data presented here suggest that 
Drosophila  p53 exhibits a combination of both 
developmental stage-specific and sex-specific 
antagonistic pleiotropy with regard to life span. If this 
result were to translate to humans, it would have 
implications for human aging related diseases such as 
cancer. Consistent with our results using flies, the 
effects of human p53 and p53-interacting genes such as 
MDM2 on cancer incidence and longevity are often sex-
biased [48], and p53 has recently been implicated in 
regulating mammalian maternal fecundity [49]. 
Moreover, during mouse development, p53 null 
mutations cause a high frequency of neural tube defects 
and lethality that preferentially affects female embryos 
[50, 51], and interestingly, this sex difference appears to 
result from the number of X chromosomes rather than 
the presence or absence of the Y [52].  The sex-specific 
effects of p53 may be related to recent observations that 
in humans the X-chromosome dosage-compensation 
gene MOF can regulate p53 [53]; and notably the MOF 
gene is conserved and also X-linked in flies. Taken 
together the data support a sexual antagonistic 
pleiotropy model in which p53 function may be 
maintained by positive selection for fecundity and/or 
survival benefit during development, in young animals, 
and under certain stress conditions, despite acting at 
another stage of the life cycle and in the other sex to 




Drosophila  culture.  Drosophila culture and life span 
assays were performed as previously described [19]. 
Briefly, crosses were conducted in 250 ml urine-
specimen bottles (Genessee Scientific) containing 35 ml 
of medium. Adult flies were maintained in narrow 
polystyrene vials (Genesee Scientific) containing 5 ml 
medium. Drosophila culture media contained cornmeal, 
agar, dextrose, yeast, and propionic acid to inhibit 
bacterial growth and tegosept to inhibit fungal growth 
[54]; except for the W cohort which were cultured on an 
older recipe containing molasses rather than dextrose 
(food recipes summarized in Supplementary Table 
S10). Flies were maintained at 25
oC and on a 12:12 
dark/light cycle, and were removed to room temperature 
for less than 1 hour every 2 days to provide fresh 
medium and remove and enumerate dead flies. To 
estimate life expectancy, single-sex mortality vials were 
established, with ~25 flies per vial (sample sizes were 
occasionally reduced due to rare escapers) and 5 or 10 
replicate vials (depending on the experiment) per sex 
for every cohort.  The L cohort deletion experiment 
used 10 replicate vials per sex, the reverse-cross 
experiments used 5 vials per sex, the stress experiments 
used 5 vials per sex, the Geneswitch experiments used 5 
vials per sex, and the drug-titration experiments used 5 
vials per sex. Note that for each line in the W cohort 
~125 flies were maintained at ~25 flies per vial with 
mates. 
 
Drosophila strains.  All Drosophila strains and 
genotypes are listed in Table 1, and several mutants and 
transgenes are diagrammed in Figure 1.  Wild-type (A-
isoform) and dominant-mutant p53 transgene stocks 
were obtained from Michael Brodsky [3] and 
Bloomington  Drosophila Stock Center.  P{UAS-
p53.Ex},  p53 wild-type. P{GUS-p53.Ct}AF51, C-
terminal fragment AA285-385, chromosome 2. P{GUS-
p53.Ct}B440, C-terminal fragment AA285-385, 
chromosome 3. P{GUS-p53.259H}, AA substitution, 
chromosome 3.  The p53 mutant strains were obtained 
from Kent Golic and Bloomington Drosophila Stock 
Center [55].  Df(3R)slo3 is deletion of entire p53 gene 
(“-”). Df(3R)Exel, P{XP-U}Exel is deletion of entire 
p53 gene (“-”). p53[5A-1-4] is 3.3kb internal deletion 
(“-”), and it’s structure was confirmed by PCR 
amplification and sequencing (diagrammed in Figure 
1B).  p53[11-1B-1] is a point mutation that introduces a 
stop codon at nucleotide residue 211, and is predicted to 
yield a 70AA truncated protein (“M”).   
P{EPgy2}p53[EY14108] is a P element insert mutation 
obtained from Bloomington Drosophila Stock Center 
(BL 20906), and the insertion was mapped to the first 
exon of the p53 B-variant using inverse PCR 
(diagrammed in Figure 1B) [56].  Because the 
p53[EY14108] mutation is predicted to produce an 
altered complement of p53 protein isoforms, it is 
grouped here with the dominant mutants (“M”).    
 
Geneswitch  conditional gene expression system.  
Geneswitch strains and protocols are as previously 
described [19-21].  The strain Act-GS-255B [19, 22] 
contains two inserts on the second chromosome of a 
construct in which the actin5C promoter drives 
expression of the Geneswitch coding region.  RU486 
(Mifepristone, Sigma) was fed to adult flies or 
developing larvae by adjusting the food to ~160ug/ml 
final concentration.  A stock solution of 3.2mg/ml of 
RU486 was prepared by dissolving drug in ethanol 
(100%). Control food received ethanol solvent alone.  In 
certain experiments RU486 concentrations were titrated 
as indicated.  All ages are expressed as days from 
eclosion at 25
oC.    To generate flies containing both the 
Act-GS-255B driver and the UAS-transgenes, virgins 
from the Act-GS-255B strain were crossed to males 
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strain as a control.  Certain crosses were done in the 
opposite direction, as indicated in the “reverse cross” 
experiments.  The life span assay result for p53-259H 
transgene over-expression in adult flies using Act-GS-
255B driver has been previously published [22], and is 
included here with additional statistical analysis for 
comparison purposes (Supplementary Table S1). 
 
Statistical analyses.  Initial cohort size was taken to be 
the number of flies in the vials at the beginning of the 
second two-day interval. Deaths during the first interval 
after transfer were considered to be due to injury during 
collection and therefore were excluded from the 
calculations. Survivorship was scored every other day 
and final cohort size was taken as summed deaths. The 
effect of p53 deletion, mutation, and over-expression on 
Drosophila life span was assayed in multiple trials for 
several lines. Life span summary statistics for each of 
the experiments (data pooled across replicate vials) and 
detailed statistical analyses are presented in the 
Supplementary Materials (Tables S1-S9).  A non-
parametric log-rank test was employed to compare the 
survival functions between p53 deficient or over-
expression genotypes and controls [57]. To further 
assess the effect of p53 on mean, median, and “maximal 
lifespan” (defined operationally here as the 90
th 
percentile of life span), 95% double bootstrap-t 
confidence intervals for the ratio of the means (or ratio 
of the percentiles) of the experimental and control 
samples were computed using a custom Fortran script. 
Mixed effects models were fit to data from each sex 
separately to ascertain the effects of mutation type (M) 
and genotype (G) (fixed main effects) on life 
expectancy, with replicate vials (R) treated as a random 
effect using the nlme package in R.  Mixed-effects 
models allow for a flexible representation of the 
covariance structure due to the grouping of the data and 
enabled the variation induced in the survival response 
by replicate vials to be characterized. As appropriate, 
the models were y = μ + M + R(M) + ε (where M = +/+, 
+/-, etc and G = 6-7, 2-6, etc was treated as an “inner” 
grouping) and y = μ + G + R(G) + ε, where ε indicates 
the within vial error variance. Post-hoc Tukey tests 
were performed to assess significant differences among 
means after correcting for multiple testing. Analyses 
were performed using the R statistical environment 
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Supplementary  Figure  S1.   Conditional  over‐
expression  of  wild‐type  and  dominant‐mutant 
p53  transgenes  using  Geneswitch  system.  All 
flies  were  the  progeny  of  the  indicated  transgenic 
strains  crossed  to  the  ubiquitous  Geneswitch  driver 
Act‐GS‐255B.  The flies were cultured in the presence 
and absence of drug, as larvae or adults, as indicated: 
M  =  males,  F  =  females,  A  =  adults,  L  =  larvae,  “+” 






over‐expression  during  development  and  effect  on 
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p53  GeneSwitch over-expression experiments Male 
M-F Target 
transgene 
Gr  N  ± SD          Mean life span 
Mean            CI  %Δ 
      Med life span 
Med            CI  %Δ 
        Max life span 
Max          CI  %Δ 
P-val Sig 
7-9 +  L-A-  120  14.25  84.6  NA 90  NA  98  NA  NA  NA 
   L+A-  123 22.48 78.44 −4.77 - −2.78  86  −9.58  - −1.58  98  −3.67  - −2.28  0.204 __ 
   L-A+  119 10.94 83.08 −4.76 - 1.25  86  −7.34  - −1.95  94  −8.41  - −1.59 6.58  ×10
-3  * 
16-9 p53-
WT[Ex] 
L-A- 122 14.76 71.11 NA 72  NA  86  NA  NA    NA 
   L+A- 0
⊗  NA NA NA  NA  NA  NA  NA  NA  NA 
   L-A+  117  12.54  75.38  2.36 - 10.37  78  5.83 - 15.51  90  1.67 – 10.11  6.97 ×10
-3  * 
18-9 p53-
Ct[AF51] 
L-A- 123 13.77 82.05 NA  86 NA  95.6  NA  NA    NA 
   L+A-  121 14.59 79.72 −6.11 - 0.77  80  −14.59 - −6.97  96  −4.65 - 6.52  0.159 _ 
   L-A+  118 11.15 79.71 −5.73 - 0.55  78  −12.89 - −9.30  96  −4.01 - 4.57  0.032 _ 
19-9 p53-
Ct[B440] 
L-A- 99  13.05 76.71 NA 78  NA  90  NA  NA  NA 
  
L+A- 
125 18.47 61.7  −23.45 - 
−15.28 






   L-A+  127 16.1  73.1  −8.26 - −0.79  76  −6. 88 - −1.93  88.8  −7.08 - 9.28  0.194 __ 
20-9 p53-259H L-A-  118  13.86  71.54 NA  72  NA  88  NA  NA  NA 
   L+A-  119 16.92 67.73 −10.46 - −0.72  70  −5.33 - 0.00  84  −10.19 - 2.22  0.069 __ 
  
L-A+ 
125 10.41 68.9  −7.11 - −0.02  70  −2.77 - 1.76  78  −15.77 - 
−5.53 
2.11 ×10
-3  * 
 
p53  GeneSwitch over-expression experiments Female 
M-F Target 
transgene 
Gr  N  ± SD          Mean life span 
Mean            CI  %Δ 
      Med life span 
Med            CI  %Δ 
        Max life span 
Max          CI  %Δ 
P-val Sig 
7-9 +  L-A-  116  9.64  92.02  NA 94  NA  102  NA  NA NA 
   L+A-  124 8.61  91.97 −3.33 - −0.72  94  −2.88 - 2.79  106  −1.41 - 3.62  2.55 ×10
-2  __ 
   L-A+  121  15.74  94.69  0.866 - 2.72  94  −4.76 - 0.00  104 2.33  –  7.41  3.10 ×10
-3  * 
16-9 p53-
WT[Ex] 
L-A- 119 16.09 88.35 NA 94  NA  100  NA  NA NA 
   L+A- 3
⊗  5.03 91.33  NA  92  NA 95.2  NA  NA  NA 
  
L-A+ 
101 22.07 74.02 −21.11 - 
−11.61 
80  −23.06 - −8.69  98  −3.39- 2.09  2.21 ×10
-6  *** 
18-9 p53-
Ct[AF51] 
L-A- 123 8.861 92.2  NA  94 NA  102  NA  NA  NA 
  
L+A- 
123 20.08 81.82 −14.90 - 
−8.03 
86  −12.87 - −5.66  100  −5.59 - 
−1.96 
3.40 ×10
-3  * 
   L-A+  125 16.53 89.18 −6.71 - −0.35  94  0.00 - 3.19  104  −3.83 - 2.28  8.57 ×10
-1  __ 
19-9 p53-
Ct[B440] 
L-A- 127 13.54 86.3  NA 90  NA  98  NA  NA NA 
  
L+A- 
125 22.35 64.56 −29.62 - 
−20.83 
70  −26.06 - 
−18.68 
85.2  −16.43 - 
−7.00 
0 *** 
   L-A+  125  14.39  89.31  1.96 - 6.81  94  4.38 - 9.12  100  0.35 - 4.09  4.72 ×10
-2  __ 
20-9 p53-259H L-A-  119  8.495  75.39 NA  76 NA  84  NA  NA  NA 
2.02 ×10
-1  88  1.80 - 8.56  __     125 22.02 70.24  76  −3.71 - 5.72  −11.94 - 
−2.49  L+A- 
4.05 ×10




















p53  wild-type dilution experiment, cohort 1 and cohort 2 combined, Male   
Gr  M-F  N  ± SD         Mean   life span       Med life span            Max  life span  P-val Sig 
 Mean         CI  %Δ        Med       CI  %Δ   Max          CI  %Δ 
No  Drug 17-9 200 17.75 59.08 NA  64 NA  74 NA  NA  NA 
4.97 ×10
-7  1:1000  17-9  204  9.92  67.68  10.54 – 19.30  68  3.63 - 8.99  78  2.48 – 8.52  ** 
1.73×10
-2  1:100  17-9  209  11.23  65.13  6.12 – 15.09  68  6.07 - 11.26  74  *  −4.77 - 3.03 
2.68 ×10
-10  1:10  17-9  203  65.13  67.89  7.60 – 19.77  70  6.84 – 12.35  78  1.27 – 8.37  *** 
1:1 17-9  1
⊗  NA  NA  NA  NA NA  NA NA  NA  NA 
 
 
p53  wild-type dilution experiment, cohort 1 and cohort 2 combined, Female   
Gr  M-F  N  ± SD       Mean   life span      Med  life span             Max  life span  P-val Sig 
 Mean              CI  %Δ     Med        CI  %Δ   Max         CI  %Δ 
No  Drug 17-9 230 18.97 59.56 NA  68 NA  76 NA  NA  NA 
6.66 ×10
-16  1:1000  17-9  221  18.39  68.15  9.29 – 19.27  72  84 5.51  -10.53  ***  −0.78 – 5.88 
1:100  17-9  217  12.90  72.26  16.92 – 26.49  74  5.29 - 12.74  84  6.79 - 13.81  0  *** 
1.35 ×10
-4  1:10  17-9  205  12.40  67.89  9.33 – 18.73  70  78  **  −0.33 – 5.89  −0.52 - 4.92 























b  Male 
M-F  Gr  N  ± SD          Mean life span 
Mean            CI  %Δ 
      Med life span 
Med            CI  %Δ 
        Max life span 
Max          CI  %Δ 
P-val Sig 
6-7   +/+ 234 14.82  74.05  NA 76  NA 88  NA  NA  NA 
3-2   -/-  ⊗178  24.53  83.07  7.13 - 16.53  90  14.26 - 23.92  98  8.84 - 11.36  0 *** 
2-6   -/+ ⊗210  13.03 73.97 −3.15 - 2.80  77  −6.11 - 4.74  86.2  −5.04 - −2.27  0.39 ___ 
2-7   -/+  195  19.83  86.86  13.22 - 21.24  92  14.31 - 24.91  100  11.88 - 15.32  0  *** 
3-6   -/+ 236 13.19  73.69  −3.26 - 2.47  74  −6.92 - 0.51  88  −1.80 - 2.91  0.13 ___ 
3-7   -/+  97  23.28  80.29  2.31 - 13.61  86  6.61 - 19.99  100  10.76 - 15.32  6.47 ×10
-10  *** 
5-6 M/+  211 16.95  58.93  −23.65 - −17.35  62  −22.11 - −11.32  82 NA  0  *** 
5-7 M/+  187 14.93  76.47  −0.25 - 6.59  78  −0.35 - 7.45  90.8  2.35 - 8.69  0.074  ___ 
8-6 M/+  241 13.77  66.85  −12.58 - −6.90  68  −13.15 - −5.58  82  −7.74 - −5.90 1.32  ×10
-11  *** 
8-7 M/+  231 17.79  76.44  −0.36 - 6.88  82  4.69 - 12.06  92  0.46 - 7.46  3.20 ×10
-3  * 
2-8   -/M 227 17.53  73.43  −4.19 - 2.36  78  −3.37 - 5.65  88  −1.78 - 2.03  0.92 ____ 
5-3 M/- 202 16.83  60.09  −22.03 - −15.76  60  −26.13 - −14.92  81.8  −6.82 - −1.26  0 *** 
5-2 M/- 235 16.79  78.09  −5.00 - 1.51  82  4.83 - 11.49  95.2  9.10 - 15.26  6.94 ×10
-6  ** 
8-3 M/- 211 17.47  72.72  −4.98 - 2.52  74  −5.63 - 0.65  92  −2.43 - 11.30  0.92 ___ 
8-5 M/M  226 16.05  59.09  −23.01 - −17.26  60  −23.30 - −15.94  78  −16.17 - −7.75  0 *** 
 
L cohort 
b  Female 
M-F  Gr  N  ± SD       Mean life span 
Mean            CI  %Δ 
        Med life span 
Med            CI  %Δ 
      Max life span 
Max          CI  %Δ 
P-val Sig 
6-7   +/+ 238 14.54  74.68  NA 76  NA 90  NA NA  NA 
3-2   -/-  242  22.22  84.47  9.00 - 16.99  88  13.07 - 21.08  102  10.47 - 19.52  0  *** 
2-6   -/+  237  9.92  79.11  3.40 - 8.62  82  7.89 - 13.22  88  −4.63 - −0.15  0.05 * 
2-7   -/+  238  20.11  81.39  5.29 - 12.64  86  10.36 - 16.84  96  3.85 - 8.92  0  *** 
3-6   -/+  225  19.67  84.29  8.96 - 16.55  88  12.47 - 19.58   96  2.24 - 8.88  0  *** 
3-7   -/+  126  14.82  89.03  15.20 - 22.93  92  15.58 - 28.32  100  8.41 - 13.49  0  *** 
5-6 M/+  212 15.32  65.82  −14.91 - −8.90  68  −13.10 - −7.01  81.8  −10.96 - −4.47 6.53  ×10
-14  *** 
5-7  M/+  227  19.18  91.32  18.39 - 26.10  96  23.53 - 30.09  106  15.00 - 21.18  0  *** 
8-6 M/+  ⊗208  21.00  89.36  15.18 - 23.80  96  23.93 - 31.21  106  14.98 - 22.09  0  *** 
8-7  M/+  210  15.27  92  19.74 - 26.56  94  NA  104  NA  0  *** 
2-8   -/M  215  20.74  89.01  15.09 - 23.10  94  23.68 - 30.52  102  8.87 - 15.67  0  *** 
5-3  M/-  225  18.15  78.90  1.89 - 9.10  84  10.53 - 13.95  92  −0.165 - 4.88  4.28 ×10
-7  ** 
5-2 M/- 221 16.31  74.37  −3.69 - 2.68  78  −0.026 - 8.22  88  −4.65 - 0.11  0.95 ___ 
8-3  M/-  231  17.70  93.8  21.72 - 29.48  98  28.95 - 33.40  102  16.92 - 22.64  0  *** 














 grouped Male 
Gr  N  ± SD       Mean   lifespan  Med  life span               Max  life span  P-val Sig 
 Mean             CI  %Δ       Med           CI  %Δ   Max          CI  %Δ 
+/+ 234 14.82  74.05  NA  76 NA  88 NA  NA  NA 
⊗178  -/-  24.53  83.07  4.92 - 14.50  90  13.09 - 22.05  98  8.84 - 11.36  0  *** 
2.04 ×10
-8 
⊗738  -/+  17.60  78.12  2.15 - 7.53  82  4.53 - 12.49  98  11.36 - 12.39  *** 
5.00 ×10
-3  +/M 870 17.48  69.54  72  88  *  −8.41 - −3.61  −7.82 -0.18  −1.20 - 0.00 
-/M 875 18.35  71.43  74  90  0.73 __  −5.86 - −0.91  −7.57 -0.29  −0.28 - 3.94 
M/M 226  16.05 49.09  60  78  0 ***  −23.06 - −17.11  −23.27 - −15.95  −16.07 - −8.02 
 
L cohort 
 grouped Female 
Gr  N  ± SD       Mean   lifespan  Med  life span               Max  life span  P-val Sig 
 Mean              CI  %Δ      Med        CI  %Δ   Max         CI  %Δ 
+/+  238  14.54 74.68 NA  76 NA  90  NA  NA  NA 
-/-  242  22.22 84.47 9.00  -17.28  88 13.09 - 20.58  102  10.50 – 19.74  0  *** 
-/+  826  17.14 82.69 8.41  -  13.59  86 13.16 - 16.86  96  1.90 – 8.85  0  *** 
⊗ 857  +/M  20.90  84.7  10.65 - 16.25  92  21.05 - 26.32  104  12.78 – 18.12  0  *** 
-/M  892  19.83 84.07 10.01  -  15.28  88 15.79 - 21.45  104  12.82 – 18.70  0  *** 
M/M 231  22.60 86.94 12.19  -  20.76  92 18.42  - 24.16  102  10.26 – 15.97  0  *** 
 
To assess the effect of p53 mutation on mean, median, and maximal lifespan, 95% double bootstrap t 
confidence intervals for the ratio of the means (or ratio of the percentiles) of the mutant and wild-type 
samples were computed as listed for the grouped L-cohort data. The mean, median, and maximal lifespan 
values are reported for each genotype as well as the P-values for the log-rank test of the null hypothesis of 
identical survival functions between wild-type and p53 mutant flies.  Note that * indicates 1.00 ×10
-3 <  P < 
5.00 ×10
-2, ** indicates  1.00 ×10
-8 P < 1.00 ×10
-3,
 *** indicates  P < 1.00 ×10
-8.  








a. Mutation type Male 
Effects   DF Num  DF 
Den 
F-val P-val  Sig   
(Intercept)  1  3106 23222.526 <0.0001 ***   
Mutation type  5  3106  57.277  <0.0001  ***   
Mutation type  Coef DF  Std.Error  t-value  P-val Adj  P-val  Sig 
(+/+)  (Intercept) 74.033  3106 1.223  60.543  <<0.0001   *** 
 (-/+)  4.065  3106  1.345  3.023    0.0025  0.028  * 
(-/-)  8.831  3106 1.787  4.943  <<0.0001 <0.001  *** 
(M/+)  -4.521  3106  1.320  -3.426    0.0006  0.007  ** 
(M/-)  -2.610  3106  1.320  -1.978    0.0480  0.338  -- 
(M/M)  -14.940  3106 1.672  -8.938  <<0.0001 <0.001  *** 
 
b. Genotype Male 
Effects   DF num  DF den  F-val  P-val  Sig     
(Intercept) 1  3097  27262.577  <0.0001  ***     
Mutation type  14  3097  49.205  <0.0001  ***     
 Genotype  Coef DF  Std.Error  t-value  P-val Adj  P-val  Sig 
6-7  (intercept) 74.0435  3097  1.153  64.194  <<0.0001   *** 
3-2 -0.139  3097  1.614  -0.086  0.931  1.000  -- 
2-6 -0.362  3097  1.565  -0.231  0.817  1.000  -- 
2-7 12.803  3097  1.647  7.775  <<.0001  <0.001  *** 
3-6 6.501  3097  2.061  3.154  0.002  0.0186  * 
3-7 8,860  3097  1.691  5.238  <<0.0001  <0.001  *** 
5-6 -15.088  3097  1.611  -9.364  <<0.0001  <0.001  *** 
5-7 -7.187  3097  1.557  -4.615  <<0.0001  <0.001  *** 
8-6 2.288  3097  1.666  1.373  0.170  0.840  -- 
8-7 2.397  3097  1.573  1.523  0.128  0.694  -- 
2-8   4.064 3097 1.568  2.593  0.010  0.0931 -- 
5-3 -13.976  3097  1.632  -8.566  <<0.0001  <0.001  *** 
5-2 -1.370  3097  1.612  -0.850  0.395  0.993  -- 
8-3 -0.646  3097  1.581  -0.409  0.683  1.000  -- 
8-5 -14.952  3097  1.583  -9.448  <<0.0001  <0.001  *** 
 
c. Mutation type Female 
Effects   DF Num  DF 
Den 
F-val P-val  Sig   
(Intercept) 1  3271  37307.36  <0.0001  ***  
Mutation type  5  3271  12.41  <0.0001  ***   
Mutation type  Coef DF  Std.Error  t-value  P-val Adj  P-val  Sig 
(+/+)  (Intercept) 74.667  3271 1.294  57.726  <<0.0001 <0.001  *** 
  (-/+)  8.040  3271 1.437  5.595  <<0.0001 <0.001  *** 
(-/-)  9.817  3271 1.783  5.506  <<0.0001 <0.001  *** 
(M/+)  10.068  3271 1.431  7.034  <<0.0001 <0.001  *** 
(M/-)  9.412  3271 1.425  6.605  <<0.0001 <0.001  *** 
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   Table S5. (cont.) 
 
d. Genotype Female 
Effects   DF num  DF den  F-val  P-val  Sig     
(Intercept) 1  3262  28493.444  <0.0001  ***     
Mutation type  14  3262  40.714  <0.0001  ***     
 Genotype  Coef DF  Std.Error  t-value  P-val Adj  P-val  Sig 
6-7  (intercept) 74.662  3262  1.240  60.228  <<0.0001   *** 
3-2 9.601  3262  1.694  5.669  <<0.0001  <0.001  *** 
2-6 4.442  3262  1.671  2.658  0.008  0.0776  -- 
2-7 6.714  3262  1.669  4.038  0.0001  <0.001  *** 
3-6 14.751  3262  2.017  7.312  <<0.0001  <0.001  *** 
3-7 9.823  3262  1.662  5.909  <<0.0001  <0.001  *** 
5-6 -8.906  3262  1.721  -5.172  <<0.0001  <0.001  *** 
5-7 14.672  3262  1.731  8.478  <<0.0001  <0.001  *** 
8-6 16.652  3262  1.689  9.856  <<0.0001  <0.001  *** 
8-7 17.510  3262  1.726  10.146  <<0.0001  <0.001  *** 
2-8   -0.291 3262 1.701  -0.171  0.8644 1.000  -- 
5-3 4.183  3262  1.694  2.470  0.0136  0.124  -- 
5-2 19.126  3262  1.682  11.372  <<0.0001  <0.001  *** 
8-3 14.410  3262  1.714  8.410  <<0.0001  <0.001  *** 
8-5 12.294  3262  1.682  7.309  <<0.0001  <0.001  *** 
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M-F  Gr  N  ± SD          Mean life span 
Mean            CI  %Δ 
      Med life span 
Med            CI  %Δ 
        Max life span 
Max          CI  %Δ 
P-val Sig 
6-7      +/+  123  10.48  53.64 NA  54 NA  69.2 NA  NA  NA 
2-3  -/-  125  18.89  63.2  11.33 - 24.50  60  1.89 – 21.56  86  6.72 – 26.42  2.62 ×10
-10  *** 
2-6      -/+  122  11.7  66.18  18.72 - 28.60  66  12.94 – 30.20  80  1.64 -18.95  0  *** 
2-7      -/+  130  9.27  79.11  42.19 -52.75  80  41.55 – 54.53  88  9.94 -29.94  0  *** 
3-6      -/+  114  15.55  43.33  −24.71 - −14.15  46  −20.74 - −11.38  57.4  −27.18 - −12.22 1.30  ×10
-8  ** 
3-7      -/+  127  11.33  67.54  21.00 - 30.88  70  23.40 – 34.64  78.8  0.34 – 19.58  0  *** 
4-6 M/+ 120  9.617  23.3 −59.34 - −53.76  20  −65.84 - −61.16  38  −53.86 - −35.26  0 *** 
4-7 M/+ 119  15.74  43.14  −24.28 - −13.92  42  −29.24 - −14.46  66  −17.60 - −2.42 1.60  ×10
-4  ** 
5-6 M/+ 124  9.25 32.02  −43.68 - −37.22  34  −39.34 - −31.90  40  −51.62 - −38.42  0 *** 
5-7  M/+  126  9.38  56.98  2.01 - 10.35  58  2.87 – 11.76  68  −14.53 - 1.27  0.038 * 
2-4   -/M 120  9.66  39.97  −28.86 - −22.20  40  −30.94 - −22.77  52  −35.37 - −22.50  0 *** 
2-5  -/M  125  7.96  59.12  6.31 – 14.34  60  6.94 – 19.48  70  −12.64 - 2.11  7.69 ×10
-4   
** 
3-4 -/M  98 15.58  26.53  −55.51 - −45.30  27  −57.20 - −49.80  50  −37.31 - −22.61  0 *** 
3-5 -/M  120  10.56  50.28  −10.41 - −2.46  52  −7.44 - 3.31  62  −20.46 - −6.79 1.32  ×10
-3  * 
4-5 M/M  72 10.77  19.89  −66.79 - −58.37  20  −64.24 - −58.24  35.4  −57.32 - −28.56  0 *** 
 
W cohort
 c Female 
M-F  Gr  N  ± SD          Mean life span 
Mean            CI  %Δ 
      Med life span 
Med            CI  %Δ 
        Max life span 
Max          CI  %Δ 
P-val Sig 
6-7      +/+  121  8.00  55.8  NA 56  NA 66  NA NA  NA 
2-3       -/-  125  6.83  63.86  11.65 - 17.66  66  11.08 – 24.48  70  −0.19 - 10.22  2.22 ×10
-16  *** 
2-6      -/+  125  7.76  55.7  −3.17 - 2.87  56  −8.38 - 3.75  62  −14.66 - −0.93  0.736 --- 
2-7      -/+  126  11.67  60.81  4.73 - 12.84  62  1.63 - 14.65  73  4.97 - 22.97  9.69 ×10
-10  *** 
3-6      -/+  121  10.29  50.38  −13.09 - −6.07  52  −15.61 - −3.58  60  −15.45 - −5.63 1.38  ×10
-4  ** 
3-7      -/+  126  10.35  67.44  17.10 - 24.67  68  11.41 – 25.88  79  13.61 - 28.76  0  *** 
4-6 M/+ 121  10.58  25.19  −57.65 - −51.46  24  −63.50 - −51.89  40  −45.03 - −32.68  0 *** 
4-7 M/+ 116  14.03  42.78  −27.51 - −19.19  42  −30.78 - −22.13  61  −12.87 - 5.36  1.39 ×10
-10  *** 
5-6 M/+ 121  9.88 38  −34.90 - −28.56  36  −44.66 - −32.95  50  −29.34 - −18.38  0 *** 
5-7  M/+  122 11.15 65.11 12.61  -  20.35  67  6.01 – 21.98  76  9.90 – 21.58  0  *** 
2-4   -/M 121  13.23  43.09  −26.96 - −18.55  48  −21.58 - −10.11  56  −20.64 - −11.77  0 *** 
2-5 -/M  125  7.80 56.77  −1.19 - 4.95  58  −3.89 - 7.78  66  −8.45 – 7.60  0.282  
3-4 -/M  117  7.14 23.5 −60.12 - −55.36  24  −58.54 - −51.52  32.8  −52.38 – −39.97  0 *** 
3-5  -/M  120 8.53  68.77 19.78  -  26.57  68  12.29 – 25.49  78  11.42 – 26.35  0  *** 
4-5 M/M  110  9.68 27.45  −53.79 - −47.70  28  −52.55 - −46.49  38  −48.59 – −39.77  0 *** 
 
To assess the effect of p53 mutation on mean, median, and maximal lifespan, 95% double bootstrap t confidence 
intervals for the ratio of the means (or ratio of the percentiles) of the mutant and wild-type samples were computed as 
listed for the  W-cohort. The log-rank test was employed to test the null hypothesis that there is no difference in the 
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   Table  S7.  Grouped  life  span  data  from  W  cohort  experiments  with  log  rank,  average,  standard  deviations,  medians  and
standard deviations of medians 
 
Group     Genotype            Sex  N  Mean Life span phenotype
a          Median Life span phenotype
b   Log Rank (vs +/+)
W cohort  
  -/-   Male  127  63.2±20.25             60±20.66      2.62e-10 
  M/-   Male  492  44.68±18.88             48±19.23      5.65e-05 
  +/-   Male  504  64.65±19.73             68±19.91        0.00 
  M/M   Male  72  19.89±10.84           20±10.82        0.00 
  +/M   Male  492  39.02±17.21           36±17.78        8e-09 
  +/+   Male  123  53.64±10.58           54±10.52     
 
    -/-    Female  125  63.9±6.49       66±6.18                       2.22e-16 
  M/-   Female  490  48.27±19.90         54±20.34          0.947 
  +/-   Female  498  58.67±12.00         58±12.13          8.27e-07 
  M/M   Female  111  27.45±10.38         28±9.96         0.00 
  +/M   Female  480  42.82±18.56         42±18.67          0.000628 
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   Table  S8.  Summary  of  the  effect  of  p53 deletion  or  mutation  on  life  span  for  the 
reverse‐cross data  
 
Reverse cross Male 





6-7  +/+  124  17.89  75.19  78 92 NA  NA  1.96 ×10
-3  * 
7-6 +/+ 126  21.08  66.4 72  88  1.96 ×10
-3  * NA  NA 
2-3 -/-  120  16.81  72.08  74  88  2.74 ×10
-2  *  2.64 ×10
-1  -- 
3-2 -/-  ⊗ 71  26.35 78.65 86  102  6.43 ×10
-5  **  1.58 ×10
-8  *** 
3-7 -/+  131  16.95  82.15  86  98  7.14 ×10
-6  *  2.90 ×10
-12  *** 
7-3 -/+  120  13.94  85.85  90  100 1.11 ×10
-9  ***  2.22 ×10
-16  *** 
6-8 +/M  115  18.34  59.04  60  83.2  5.35 ×10
-11  ***  4.15 ×10
-4  ** 
8-6 +/M  129  13.99  67.64  66  84  2.89 ×10
-6  **  2.06 ×10
-1  -- 
7-8 +/M  122  17.02  81.25  84  100 9.69 ×10
-6  **  7.28 ×10
-11  *** 
8-7 +/M  117  22.92  74.97  76  102 3.77 ×10
-3  *  3.33 ×10
-6  *** 
3-8 -/M 125  21.50  75.98  78  102 2.80 ×10
-2  *  5.31 ×10
-6  *** 
8-3 -/M 125  17.39  65.10  66  80  1.92 ×10
-7  **  5.74 ×10
-2  -- 
5-8  M/M 119 22.11 61.28 62  88  1.85 ×10
-6  **  1.07 ×10
-1  -- 
8-5  M/M 122 16.77 58.21 59  79.6 1.70 ×10
-13  ***  3.31 ×10
-5  ** 
 
Reverse cross Female 





6-7  +/+  123 21.24 72.44  74  92  NA  NA  4.09 ×10
-4  ** 
7-6  +/+  125 11.62 82.54  86  94  4.09 ×10
-4  ** NA  NA 
2-3  -/-  122 21.9  88.23  94  103.8 0  *** 1.35 ×10
-14  *** 
3-2  -/-  121 15.84 95.77  98  110  0  *** 0  *** 
3-7  -/+  123 27.64 84.59  92  101.6 0  *** 1.58 ×10
-14  *** 
7-3  -/+  126 5.985 90.94  92  100  0  *** 2.96 ×10
-10  *** 
6-8  +/M  124 31.88 87.37  100  108  0  *** 0  *** 
8-6  +/M  116 15.76 97.45  100  108  0  *** 0  *** 
7-8  +/M  125 15.99 93.94  98  106  0  *** 0  *** 
8-7  +/M  122 14.68 94.84  96  107.8 0  *** 0  *** 
3-8 -/M 123  25.27  96.6 104 114 0  ***  0  *** 
8-3 -/M 121  22.74  101.3  108 112 0  ***  0  *** 
5-8  M/M 122 19.76 96.49  100  111.8 0  *** 0  *** 
8-5  M/M 118 24.12 88.34  94  106.6 0  *** 2.32 ×10
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   Table S9. Summary of the effect of p53 deletion on life span when flies were subject to ionizing radiation 
or a 100% oxygen environment 
 
Stress experiments Male 
M-F  Gr  N  ± SD    Mean life span  Med life span  Max life span  P-val Sig 
     
 Mean        CI  %Δ   Med        CI  %Δ   Max        CI  %Δ 
                Standard conditions 
6-7  +/+ 129 17.12 79.81 NA 82  NA 98  NA NA  NA 
7.84 ×10
-6  2-3  -/-  117 13.14 75.56  78  88  **  −9.12 - −1.15  −7.64 - −1.03  −14.36 – 7.09 
3-7  -/+  124 15.96 79.81  82  98  0.73 ---  −4.18 - 4.43  −5.30 - 4.00  −5.52 – 3.24 
                          Ionizing radiation  
6-7  +/+ 274 5.78  40.82 NA 42  NA 46  NA   NA  NA 
2-3 -/- 273  5.43 33.12  34  38  0 ***  −20.68 - −17.06  −25.54 - −19.05  −22.65 - – 12.41 
2.02 ×10
-7  3-7  -/+  273  6.15  42.39  1.80 - 6.00  42  47.6  **  −7.48 - 0.00  −1.24 – 11.02 
                             100% O2  
6-7  +/+ 238 0.56  17.83 NA 18  NA 18  NA NA  NA 
2-3 -/- 232  1.56 15.16  16  16  0 ***  −16.13 - −14.10  −11.11 - −11.11  −11.11 - −11.11 
4.44 ×10
-16  3-7 -/+  244  1.05 17.16  18  NaN - NaN  18  NaN-NaN  ***  −4.38 - −3.05 
 
Stress experiments Female 
M-F  Gr  N  ± SD    Mean life span  Med life span  Max life span  P-val Sig 
     
 Mean        CI  %Δ   Med        CI  %Δ   Max        CI  %Δ 
                    Standard conditions 
6-7  +/+ 126 19.49 82.78  NA 88  NA  96  NA NA  NA 
9.02 ×10
-5  2-3  -/-  123  13.13  89.17  3.77 – 12.09  90  100  1.29  - 6.42  **  −2.90 -4.99 
2.10 ×10
-7  3-7 -/+  123  19.56  88.34  1.60  -11.64  92  100  1.21 - 7.20  **  −0.21 - 6.87 
                            Ionizing radiation  
6-7  +/+ 280 13.79 48.27  NA 50  NA  60  NA NA  NA 
2.98 ×10
-4  2-3  -/-  270  9.22  54.38  9.09 – 16.71  56  7.67 – 16.15  62  **  −3.92 - 4.63 
3-7  -/+  271  17.12  51.17  13.13 – 23.36  62  18.57 – 28.81  72  12.21 - 21.04  0  *** 
                           100% O2  
6-7  +/+ 238 0.367 17.97  NA 18  NA  18  NA   NA  NA 
1.28 ×10
-13  2-3 -/- 242  1.49 17.22  18  NaN - NaN  18  NaN - NaN  ***  −5.06 - −3.34 
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Table S10.  Summary of food (fly culture media) recipes
  
For One Liter  Old Food  New Food 
Water (L)  1 1 
Sucrose (g)  0  0 
Dextrose (g)  0  105 
Molasses (ml)  100  0 
Agar (g)  9  8 
Yeast (g)  41  26 
Cornmeal (g)  100  50 
Tegosept (g)  2.5  1.7 
95% Ethanol (ml)  22.5  8.6 
Propionic Acid (ml)  8  1.9 
phosphoric acid  0  0 
 
The W cohort was cultured on “Old food” recipe, as were all flies 
in  experiments  in  Tower  laboratory  prior  to  September  2005.  
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